Pfizer just struck a $5.2 billion deal for an eczema drugmaker
Thomson Reuters
Anacor already has one approved drug (a topical anti-fungal treatment), but the big draw for Pfizer is a drug called crisaborole to treat eczema, an inflammatory skin condition.
The gel treatment is in the FDA filing process and should be decided on by January 2017, and Pfizer said in a release that it expects peak yearly sales for the drug to hit $2 billion.
In April, the drugmaker's $160 billion megamerger with Allergan was scrapped after the US Treasury released new rules governing so-called tax inversions that undercut the deal's key rationale. Since then, there have been reports that Pfizer is also interested in cancer drugmaker Medivation.
Ultimately, Pfizer (which has both innovative and established sides) is headed for a split-up of the company, which it's expected to give an update on by than the end of 2016. The Anacor acquisition would fit in with that plan by building up the company's inflammation portfolio.
- 2 states where home prices are falling because there are too many houses and not enough buyers
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- 9 health benefits of drinking sugarcane juice in summer
- 10 benefits of incorporating almond oil into your daily diet
- From heart health to detoxification: 10 reasons to eat beetroot
- Why did a NASA spacecraft suddenly start talking gibberish after more than 45 years of operation? What fixed it?
- ICICI Bank shares climb nearly 5% after Q4 earnings; mcap soars by ₹36,555.4 crore